S&P 500
(1.26%) 5 127.79 points
Dow Jones
(1.18%) 38 676 points
Nasdaq
(1.99%) 16 156 points
Oil
(-1.22%) $77.99
Gas
(5.65%) $2.15
Gold
(0.02%) $2 310.10
Silver
(-0.16%) $26.79
Platinum
(0.37%) $966.20
USD/EUR
(-0.35%) $0.929
USD/NOK
(-1.07%) $10.87
USD/GBP
(-0.11%) $0.797
USD/RUB
(0.35%) $91.45

Actualizaciones en tiempo real para Candel Therapeutics, Inc. [CADL]

Bolsa: NASDAQ Sector: Healthcare Industria: Biotechnology
Upcoming Earnings Alert

4 days till quarter result
(bmo 2024-05-09)

Expected move: +/- 11.93%

Última actualización3 may 2024 @ 16:00

7.00% $ 9.02

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):
Our systems believe the stock currently is overvalued by 0.09% compare to its pairs and should correct downwards.
Profile picture for Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma...

Stats
Volumen de hoy 999 743
Volumen promedio 5.44M
Capitalización de mercado 264.71M
EPS $-0.290 ( 2023-11-09 )
Próxima fecha de ganancias ( $0 ) 2024-05-09
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -6.89
ATR14 $0.0330 (0.37%)
Insider Trading
Date Person Action Amount type
2024-01-12 Schoch Charles Sell 0 Common Stock
2024-01-12 Schoch Charles Sell 0 Common Stock
2024-01-12 Schoch Charles Sell 25 000 Stock Option (Right to Buy)
2024-01-12 Schoch Charles Sell 39 498 Stock Option (Right to Buy)
2023-11-28 Tyagarajan Seshu Sell 17 328 Common Stock
INSIDER POWER
76.72
Last 92 transactions
Buy: 8 106 969 | Sell: 4 393 086
Correlación (AI algo v.1.1b): Overvalued: -0.09% $9.19 paired level. (El Algoritmo Rastrea Los Cambios De Las Acciones Más Correlacionadas En Tiempo Real Y Proporciona Una Actualización Instantánea)

Volumen Correlación

Largo: 0.05 (neutral)
Corto: 0.45 (neutral)
Signal:(33.833) Neutral

Candel Therapeutics, Inc. Correlación

10 Correlaciones Más Positivas
SCTL0.94
MESO0.938
LABP0.929
SMTC0.925
MOTNU0.923
NN0.918
QRHC0.916
PAYS0.916
STOK0.915
SRTS0.913
10 Correlaciones Más Negativas
ATHN-0.936
PTRA-0.923
ARIZ-0.92
AEY-0.902
LUCD-0.895
ONEM-0.89
EZGO-0.89
LULU-0.886
SFT-0.881
AFYA-0.878

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Candel Therapeutics, Inc. Correlación - Moneda/Commodity

The country flag 0.33
( neutral )
The country flag 0.43
( neutral )
The country flag 0.00
( neutral )
The country flag 0.38
( neutral )
The country flag 0.24
( neutral )

Candel Therapeutics, Inc. Finanzas

Annual 2023
Ingresos: $0
Beneficio Bruto: $-1.20M (0.00 %)
EPS: $-1.310
FY 2023
Ingresos: $0
Beneficio Bruto: $-1.20M (0.00 %)
EPS: $-1.310
FY 2022
Ingresos: $125 000
Beneficio Bruto: $-862 000 (-689.60 %)
EPS: $-0.0994
FY 2021
Ingresos: $0.00
Beneficio Bruto: $0.00 (0.00 %)
EPS: $-1.934

Financial Reports:

No articles found.

Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

Acerca de Señales en Vivo

Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.

Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico